The Parkinson’s Discovery on the Real FDA Road

This is NOT medical advice and NOT a cure claim. It maps the Parkinson’s Mechanism Analysis license onto the real FDA approval road, explains what happens if it is never accepted as a drug, and shows the one lawful way it can still reach people — as a dietary supplement (which by law cannot claim to treat Parkinson’s).

01   How to read this

Start with the master guide, then this page, then the giveaway itself:

• The True-to-Life Method of Filing an FDA-Approved Medicine — the full approval road, start to finish.
• This page — the Parkinson’s discovery placed on that road.
• Sister companions: The Diabetes Discovery and The Alzheimer’s Discovery on the Real FDA Road.
• The licensed package itself: Licensed Research: Parkinson’s Mechanism Analysis.

All are in the Licensed Research category: cri-one.com/store/licensed-research.html.

02   What the Parkinson’s discovery actually is

The strongest of the three giveaways — the only one whose lead direction already has human PD trial data, and the only one with a genuinely novel compound class:

For context, L-DOPA — the gold-standard PD drug — is itself a C-H-O-N compound, so the chemistry is in the right neighborhood.

Intellectual property: patent application #19/445,644, Patent Pending (per the package).

03   Where it sits on the FDA road

Stage 0 — Discovery & Preclinical  ·  YOU ARE HERE (pre-IND) *
Stage 1 — IND application (Form 1571) · not yet started
Stage 2 — Phase 1 / 2 / 3 trials · not yet started
Stage 3 — NDA filing (Form 356h) · not yet started
Stage 4 — FDA review + cGMP inspection · not yet started
Stage 5 — Approval decision · not yet reached
Stage 6 — Post-market · not yet reached

* The NAC direction already has independent human PD data — but the work was done by outside researchers, NAC is still NOT an FDA-approved PD drug, and this package would still need the full road. The novel zinc-halogen class has NO data and starts from scratch.

• Endpoints: the MDS-UPDRS rating scale and daily “OFF” time. DaTscan is a useful biomarker but is NOT an FDA-accepted stand-alone efficacy endpoint.
• Two sub-paths: NAC could pursue larger confirmatory trials; the novel zinc-halogen class must start at basic chemistry, then animal safety.
• Disease-modification is brutally hard and has defeated many funded programs.

“Patent #19/445,644” is not “FDA-approved.” Patent Pending and real human NAC data still place this at Stage 0 of the safety-and-efficacy road.

04   What if there is no acceptance?

• Clinical hold — especially likely for the novel zinc-halogen class with no prior data.
• Trial failure — no MDS-UPDRS benefit, or a safety signal. Only ~1 in 10 drugs entering trials is approved; PD disease-modification is harder still.
• Refuse-to-File / Complete Response Letter — approval withheld pending fixes.
• No funding at all — the most likely case; 10–15 years and hundreds of millions of dollars without a pharma partner.

If any happen, three honest options remain: license/sell the pending patent, keep it open as licensed research (the novel class deserves independent eyes), or make it as a dietary supplement — the one route that needs no FDA approval.

05   The one lawful way to make it: a dietary supplement

A dietary supplement is the only ingestible health product an independent maker can lawfully sell without FDA pre-approval (DSHEA, 1994). The trade: it may never claim to diagnose, treat, cure, or prevent a disease — “treats Parkinson’s” or “raises dopamine” makes it an illegal unapproved drug.

1. Use only legal dietary ingredients. Magnesium and zinc are established. NAC is a special case — technically excluded (drug-first), but under FDA enforcement discretion (2022 guidance), with a proposed rule (~2026) to formally permit it. Confirm current status first.
2. The novel zinc-halogen compounds almost certainly cannot go in a supplement — post-1994, would require an NDI notification (75 days, with safety evidence), and may not qualify as dietary ingredients. Leave them out until settled in a lab.
3. Manufacture under supplement cGMP (21 CFR Part 111).
4. Label per 21 CFR 101 (Supplement Facts panel, ingredients, directions, warnings).
5. Make only structure/function claims; include the FDA disclaimer; notify the FDA within 30 days; hold substantiation.
6. Stay responsible for safety; report serious adverse events.

Required on every structure/function claim: “This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.”

Bottom line: reachable without FDA approval — an antioxidant/brain-support product built around NAC, magnesium, and low-dose zinc — but it can never name Parkinson’s, and the novel discovery (the most exciting part) stays on the shelf until it is studied. That gap is the frustrating part.

Inquiries

Christopher Gabriel Brown — Inventor & Licensor

crioneaka@outlook.com  · 
1341 Wellington Cove, Lawrenceville, GA 30043-5255, USA

Related work by the same author: Chemical Cooker Laboratory — cri-one.com/store/chemical-cooker-laboratory.html

Educational only. Not medical, legal, or regulatory advice; not a claim that any compound is a cure; not affiliated with or endorsed by the FDA or USPTO. The discovery is supplement-grade research, not an FDA-approved drug. Dietary-supplement rules (DSHEA, NDI, 21 CFR 101/111) and the NAC enforcement-discretion policy change over time — confirm current requirements with the FDA and qualified counsel before manufacturing or labeling anything. Do not self-treat; consult a licensed physician. USA buyers only; sales subject to Georgia (Gwinnett County) law.

© 2026 Christopher Gabriel Brown. All rights reserved. “Cri-One” and “Licensed Research” are product designations of the licensor. Patents retained; not sold.